Hexacath Belgium SRL
Hexacath Belgium reported total assets of 96,025 € at the end of the 2025 financial year (annual accounts filed with the NBB on 19 Aug 2026).
The score of Hexacath Belgium shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -15 % Total assets -25 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Hexacath Belgium's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 19 Aug 2026
- Year ended 31 Dec 2024filed on 23 Jun 2025
- Year ended 31 Dec 2023filed on 24 Jun 2024
- Year ended 31 Dec 2022filed on 28 Jun 2023
- Year ended 31 Dec 2021filed on 12 May 2022
Hexacath Belgium's financial analysis
- Solvency83.8%sector median: 32.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Hexacath Belgium
Hexacath Belgium's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0863.575.360
- VAT number
- BE0863575360
- Peppol
- Not found on Peppol as of 10 Nov 2026 · Check
- Legal form
- SRL
- Incorporated
- 20 Feb 2004
- Registered office
- 1050 Ixelles
- Latest accounts
- 2025 · filed on 19 Aug 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Hexacath Belgium (SRL) has been based in Ixelles since 2004, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 6,066 € and equity of 80,482 €; its revenue is not published. Its solvency stands at 83.8%, above the median of its sector (32.3%).
Companies similar to Hexacath Belgium
Companies in the same business, of comparable size and area, outside its group.
- Taikun Pharmaceutical Technology Manufacture of basic pharmaceutical products Ghent · balance sheet 275,396 €
- Mandible Guide Research and experimental development on natural sciences and engineering Woluwe-Saint-Pierre · balance sheet 64,270 €
- AlphaCare Wholesale of pharmaceutical and medical goods Grez-Doiceau · balance sheet 559,557 €
- Alnylam Belgium Wholesale of pharmaceutical and medical goods Brussels · balance sheet €1.20m
- Corcym Belgium Wholesale of pharmaceutical and medical goods Saint-Josse-ten-Noode · balance sheet €1.30m
- Confort AT Home Wholesale of pharmaceutical and medical goods Anderlecht · balance sheet 7,413 €
- RevaTis Manufacture of pharmaceutical preparations Marche-en-Famenne · balance sheet €4.12m
- Formac Pharmaceuticals Research and experimental development on natural sciences and engineering Leuven · balance sheet 2,112 €
Frequently asked questions about Hexacath Belgium
What is the revenue of Hexacath Belgium?
Hexacath Belgium files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Hexacath Belgium?
In Belgium, the VAT number is the company number prefixed with BE: BE0863575360 for Hexacath Belgium, if the company is VAT-registered. Its company number (CBE) is 0863.575.360.
Where is the registered office of Hexacath Belgium?
According to the CBE register, the registered office of Hexacath Belgium is in 1050 Ixelles.
What is the equity of Hexacath Belgium?
At the close of the 2025 financial year, the equity of Hexacath Belgium amounts to 80,482 €, a solvency of 83.8% of total assets.
Who manages Hexacath Belgium?
The register lists 1 active mandates at Hexacath Belgium. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Hexacath Belgium
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →